Trial Profile
Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms LADI
- 13 Oct 2022 Planned End Date changed from 1 Jul 2022 to 1 Oct 2022.
- 13 Oct 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Oct 2022.
- 11 Oct 2022 Primary endpoint (Cumulative incidence of persistent disease flares) has been met according to Results presented at the 30th United European Gastroenterology Week.